{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
21 CFR 346
(2004)
Source URL:
First approved in 2004
Source:
21 CFR 346
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT03530930: Phase 4 Interventional Completed Osteoarthritis
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Class:
STRUCTURALLY DIVERSE